RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
RIGL$42.05+6.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | Year Ended December 31, | ||||||||
| | 2023 | 2022 | 2021 | ||||||
| Operating activities | | | | | | | | | |
| Net loss | $(25,091) | | $(58,573) | | $(17,914) | | |||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | | | | | | | | | |
| Stock-based compensation expense | 8,806 | | 12,385 | | 9,486 | | |||
| Loss (gain) on sale and disposal of fixed assets | | 266 | | | (138) | | | — | |
| Depreciation and amortization | 1,238 | | 998 | | 1,162 | | |||
| Non-cash interest expense | | — | | | 682 | | | 3,139 | |
| Net amortization and accretion of discount on short-term investments and term loan | | (479) | | | (63) | | | 287 | |
| Changes in assets and liabilities: | | | | | | | | | |
| Accounts receivable, net | 9,770 | | (24,848) | | 501 | | |||
| Inventories | | 1,172 | | | (2,377) | | | (4,875) | |
| Prepaid and other current assets | 1,998 | | (847) | | 6,633 | | |||
| Other assets | 56 | | 334 | | (150) | | |||
| Right-of-use assets | 1,069 | | 7,773 | | 8,192 | | |||
| Accounts payable | (366) | | 3,788 | | 41 | | |||
| Accrued compensation | (190) | | (1,824) | | 1,098 | | |||
| Accrued research and development | (4,195) | | (2,676) | | 5,495 | | |||
| Revenue reserves and refund liability | | 3,539 | | | 4,230 | | | 1,850 | |
| Other accrued liabilities | (1,151) | | 1,709 | | (24) | | |||
| Lease liability | | (1,128) | | | (8,546) | | | (8,621) | |
| Deferred revenue | | (14) | | | (1,227) | | | (422) | |
| Other current and long-term liabilities | (1,043) | | (4,538) | | — | | |||
| Net cash (used in) provided by operating activities | (5,743) | | (73,758) | | 5,878 | | |||
| Investing activities | | | | | | | | | |
| Maturities of short-term investments | 41,650 | | 101,228 | | 62,050 | | |||
| Purchases of short-term investments | (31,206) | | (28,894) | | (141,459) | | |||
| Purchases of intangible asset | (15,000) | | — | | | | |||
| Proceeds from sale of property and equipment | | 259 | | | 893 | | | — | |
| Purchases of property and equipment | — | | (450) | | (627) | | |||
| Net cash (used in) provided by investing activities | (4,297) | | 72,777 | | (80,036) | | |||
| Financing activities | | | | | | | | | |
| Net proceeds from term loan financing | | 19,950 | | | 19,542 | | | — | |
| Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan | 1,049 | | 2,124 | | 4,775 | | |||
| Cost share advance from a collaboration partner | | — | | | — | | | 57,900 | |
| Cost share payments to a collaboration partner | | (2,632) | | | (15,116) | | | — | |
| Net cash provided by financing activities | 18,367 | | 6,550 | | 62,675 | | |||
| Net increase (decrease) in cash and cash equivalents | 8,327 | | 5,569 | | (11,483) | | |||
| Cash and cash equivalents at beginning of period | 24,459 | | 18,890 | | 30,373 | | |||
| Cash and cash equivalents at end of period | $32,786 | | $24,459 | | $18,890 | | |||
| Supplemental disclosure of cash flow information | | | | | | | | | |
| Interest paid | $5,848 | | $2,495 | | $1,500 | | |||
| Purchases of intangible asset included within accounts payable | $— | | $15,000 | | $— | | |||
** RIGEL PHARMACEUTICALS, INC.**
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.